July 21st 2025
Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.
July 18th 2025
Take a look back through some of the top stories from the first half of the year.
July 17th 2025
The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
July 16th 2025
The Continuity Grant will support projects in bladder cancer and/or upper tract urothelial carcinoma that were previously scientifically reviewed, approved, and funded.
Alpha1H was granted a fast track designation in November 2023.
GU Tumor Board: Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
September 27, 2025
Register Now!
Urologic surgeons successfully complete world’s first bladder transplant
The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.
Non–Muscle Invasive-Bladder Cancer Overview
Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk categories and corresponding treatment pathways.
Laura Davis, MD, on link between microplastics and bladder cancer
“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD.
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
The phase 3 RC48-C016 trial met its primary end points.
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
The study was published in JCO Oncology Practice.
Durvalumab plus BCG significantly improves DFS in NMIBC
The data are to be presented at an upcoming medical conference.
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
The CR rate was 71% in patients with BCG-unresponsive NMIBC with CIS with or without papillary disease.
Physical function and frailty measures offer distinct insights in patients with bladder cancer
Data showed that physical function and self-reported frailty assessments were poorly correlated.
FDA to host advisory committee meeting on UGN-102 for NMIBC
The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.
Expert discusses the NMIBC trials landscape
"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
“In this well-selected patient population, it is possible to treat with systemic therapy alone," says John L. Gore, MD, MS.
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
“[These are] very good numbers for these patients who otherwise would undergo a radical cystectomy," says Félix Guerrero-Ramos, MD, PhD, FEBU.
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
The sBLA for NAI was submitted to the FDA in March 2025.
FDA updates in urology: April 2025
A recap of the FDA submissions and regulatory decisions in urology from April 2025.
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.
Cxbladder Triage may help patients avoid unnecessary cystoscopies
The study population was able to avoid 952 cystoscopies and 70 CT scans, according to the investigators.
Nogapendekin alfa inbakicept shows high CR, avoidance of cystectomy in NMIBC
In cohort A, the cystectomy-free rate at 36 months was 84%.
UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.
Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC
The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
Cretostimogene yields high CR rate in BCG-unresponsive NMIBC
"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.
CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC
“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
ADVANCED-002: High CR rates observed with TARA-002 in high-grade NMIBC
Treatment with TARA-002 was associated with a 100% high-grade CR at any time in BCG-unresponsive participants.
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial.
Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan
Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
AUA 2025: What to watch for in urologic oncology
We preview several noteworthy P2 presentations in the urologic oncology space.
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Merrill discusses the evolving non–muscle invasive bladder cancer treatment space.
NMIBC Clinical Forums highlight novel therapies and treatment strategies
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
Darolutamide plus ADT approved in EU for mHSPC
Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC
Experts urge FDA to remove black box warning on low-dose vaginal estrogen
Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet